Healthcare
Live Price
Offline$221.38
+0.00% today
Window Change
+392.50%
Window
Jun 23, 2025 → Jan 8, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 139 bars · Jun 23, 2025 → Jan 8, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cidara Therapeutics, Inc. (CDTX) is a Healthcare stock with a market cap of $5.61B. The stock last traded around $221.38 and up 392.5% across the available one-year price window (Jun 23, 2025 → Jan 8, 2026). Baseline metrics include revenue growth of -94.5%, EPS growth of -409.5%, a dividend yield of 0.0%. What stands out right now is revenue -94.5%, EPS -409.5%, free cash flow -670.2% with operating margin 0.0% and ROIC -46.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CDTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CDTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CDTX Max Drawdown
-19.83%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CDTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$12.1M
-75.7% YoY
FY Net Income
-$72.1M
-69.8% YoY
Free Cash Flow
-$54.6M
-116.0% YoY
Revenue Growth
-94.5%
EPS Growth
-409.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 1M | 23M | 64M | 50M | 12M |
| Gross Profit | 1M | -13M | 64M | -24M | 12M |
| Operating Income | -176M | -27M | -34M | -42M | -72M |
| EBITDA | -176M | -27M | -33M | -42M | -71M |
| Net Income | -170M | -23M | -34M | -42M | -72M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 190M | 36M | 33M | 62M | 36M |
| Total Assets | 215M | 67M | 47M | 75M | 60M |
| Total Liabilities | 51M | 75M | 62M | 54M | 50M |
| Shareholder Equity | 163M | -8M | -14M | 22M | 11M |
| Total Debt | 4M | 5M | 1M | 5M | 8M |
| Net Debt | -186M | -31M | -32M | -57M | -28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
-115.6% YoY
Capital Expenditures
186K
-353.7% YoY
Free Cash Flow
55M
-116.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.1%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.